187 related articles for article (PubMed ID: 34289557)
1. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
[No Abstract] [Full Text] [Related]
2. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
4. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
5. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon CH; Wang QE; Devine SM; He X; Bai XF; Hofmeister CC; Yu J
Clin Cancer Res; 2014 Aug; 20(15):3989-4000. PubMed ID: 24677374
[TBL] [Abstract][Full Text] [Related]
6. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
Chen W; Xian N; Lin S; Liao W; Chen M
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
[TBL] [Abstract][Full Text] [Related]
7. [Construction of CAR-T cells targeting CS1 and analysis of their antitumor activity in vitro].
Zhang W; Wang C; Tao Z; Yin C; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2162-2170. PubMed ID: 33169580
[TBL] [Abstract][Full Text] [Related]
8. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.
Luo H; Su J; Sun R; Sun Y; Wang Y; Dong Y; Shi B; Jiang H; Li Z
Clin Cancer Res; 2020 Oct; 26(20):5494-5505. PubMed ID: 32816947
[TBL] [Abstract][Full Text] [Related]
10. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.
Rosenzweig M; Urak R; Walter M; Lim L; Sanchez JF; Krishnan A; Forman S; Wang X
Cytotherapy; 2017 Jul; 19(7):861-866. PubMed ID: 28483281
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
12. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
[TBL] [Abstract][Full Text] [Related]
14. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
O'Neal J; Ritchey JK; Cooper ML; Niswonger J; Sofía González L; Street E; Rettig MP; Gladney SW; Gehrs L; Abboud R; Prior JL; Haas GJ; Jayasinghe RG; Ding L; Ghobadi A; Vij R; DiPersio JF
Leukemia; 2022 Jun; 36(6):1625-1634. PubMed ID: 35422095
[TBL] [Abstract][Full Text] [Related]
15. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
16. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
17. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N
Front Immunol; 2024; 15():1389018. PubMed ID: 38720898
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19.
Tokunaga Y; Sasaki T; Goto S; Adachi K; Sakoda Y; Tamada K
Mol Cancer Ther; 2022 Jan; 21(1):138-148. PubMed ID: 34675119
[TBL] [Abstract][Full Text] [Related]
19. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
Meng M; Wu YC
J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
[TBL] [Abstract][Full Text] [Related]
20. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
